Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
2026-04-07 12:03:13 ET
Investment Overview
Towards the end of January this year, I upgraded my rating on Amgen Inc. ( AMGN ) stock from a Hold (issued in a note from February 2025 ) to a Buy, noting that the Thousand Oaks, California-based Pharma giant:
has grown revenues at a decent clip in recent years - partly due to its acquisition of Horizon Therapeutics in October 2023, which brought an additional ~$4bn of revenues in in 2025, thanks to gout therapy Krystexxa, thyroid eye disease med Tepezza, and Uplizna, indicated for Neuromyelitis optica ("NMO").
In 2025, Amgen also secured five new FDA product approvals - and boasts no fewer than fourteen "blockbuster" (revenues >$1bn per annum) drug products.
Read the full article on Seeking Alpha
For further details see:
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
NASDAQ: RHHVF
RHHVF Trading
7.72% G/L:
$417 Last:
1,607 Volume:
$402 Open:
